Clinical trials: Hodgkin Lymphoma
Diffuse Large B Cell Lymphoma
Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL
To evaluate the tolerability,feasibility, and efficacy of combining acalabrutinib with RICE chemotherapy as second line therapy in relapsed/refractory DLBCL patients with separate primary objectives in each of in two cohorts…
- Trial name
- NCT03736616
- Testing
- Carboplatin, Ifosfamide, Etoposide
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Swedish Medical Center
Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma
Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas
This research is being done to assess the effectiveness and safety of acalabrutinib combined with lisocabtagene maraleucel (liso-cel) for people with relapsed/refractory aggressive B-cell lymphoma.
- Conditions
- Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL, Diffuse Large B-cell Lymphoma (DLBCL)
- Trial name
- NCT05583149
- Testing
- ACALABRUTINIB, LISOCABTAGENE MARALEUCEL, Lymphodepleting chemotherapy
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Patrick C. Johnson, MD
Lymphoma, Extranodal NK-T-Cell
18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell Lymphoma
The purpose of this study is to evaluate whether 18F-FDG PET/CT-based prognostic model of NK/T-cell lymphoma can predict disease progression
- Trial name
- NCT03051555
- Testing
- 18F-FDG PET/ CT
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University Cancer Hospital & Institute
Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
This phase II trial is studying the side effects and best dose of alemtuzumab when given together with fludarabine phosphate and total-body irradiation followed by cyclosporine and mycophenolate mofetil in treating patients who…
- Conditions
- Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Nasal Type Extranodal NK/T-cell Lymphoma
- Trial name
- NCT00118352
- Testing
- alemtuzumab, total-body irradiation, fludarabine phosphate
- Where
- 2 sites in United States, Italy
- Volunteers
- 12 people
- Sponsor
- Fred Hutchinson Cancer Center
Cutaneous T Cell Lymphoma, Mycosis Fungoides
Photopheresis in Early-stage Mycosis Fungoides
The purpose of this study is to determine whether photopheresis therapy can be used to improve the clinical course of early stage cutaneous T-cell lymphoma (CTCL).
- Trial name
- NCT05680558
- Testing
- UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis, THERAKOS® CELLEX photopheresis system
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Columbia University
Covid19
Prone Positioning in Non-intubated Patients With COVID-19 Associated Acute Respiratory Failure
Besides protective ventilation with low tidal volumes, prone positioning is a proven intervention to decrease mortality in mechanically ventilated patients with moderate-severe acute respiratory distress syndrome.
- Trial name
- PRO-CARF (NCT04477655)
- Testing
- Awake prone positioning, Standard oxygen therapy
- Where
- 2 sites in Mexico
- Volunteers
- 430 people
- Sponsor
- Hospital Civil de Guadalajara
Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)
A Prospective Study of Response-adapted Low-dose Radiotherapy Combined With Orelabrutinib for Localized Mucosa-associated Lymphoid Tissue Extranodal Marginal Zone Lymphoma
Multi center, randomized, controlled, prospective clinical trial to explore the clinical efficacy and safety of low-dose radiotherapy combined with targeted therapy for localized MALT lymphoma.
- Trial name
- NCT07705308
- Testing
- Radiation (Very low dose), Radiation (Standard)
- Where
- 3 sites in China
- Volunteers
- 140 people
- Sponsor
- Ruijin Hospital
Classical Hodgkins Lymphoma in Children and Adolescents.
Treatment for Classical Hodgkin Lymphoma in Children and Adolescents
Reduction of the indication for radiotherapy (RT) in newly diagnosed patients with classical Hodgkins lymphoma without compromising cure rates.
- Trial name
- EuroNet-PHL-C2 (NCT02797717)
- Testing
- Radiotherapy:, Vincristine, Etoposide
- Where
- Israel
- Volunteers
- 2,200 people
- Sponsor
- GALIA AVRAHAMI
Mantle Cell Lymphoma
Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)
This is a phase I/II trial of bortezomib, cladribine, and rituximab in newly diagnosed and relapsed mantle cell lymphoma (MCL). The phase I component has three dose levels of cladribine (3 mg/m2, 4 mg/m2, and 5 mg/m2) and is…
- Trial name
- NCT01439750
- Testing
- Rituximab, bortezomib, Cladribine
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Milton S. Hershey Medical Center
Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma
Copanlisib Plus Venetoclax in R/R DLBCL
This research study is evaluating the combination of two drugs, copanlisib and venetoclax, as a possible treatment for trelapsed/refractory diffuse large B-cell lymphoma (DLBCL) The names of the study drugs involved in this study…
- Conditions
- Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
- Trial name
- NCT04572763
- Testing
- Copanlisib, Venetoclax
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Dana-Farber Cancer Institute
Burkitt Lymphoma
Recommendations for the Treatment of Children With Burkitt's Lymphoma
This is the 4th LMB study by the French African Pediatric Oncology Group (GFAOP). The study hopes to be able to evaluate children earlier with stage I and II disease and to evaluate treatment response earlier so that the units…
- Trial name
- GFALMB2019 (NCT04425421)
- Testing
- OBSERVATIONAL
- Where
- 7 sites in Burkina Faso, Côte d’Ivoire and 4 more
- Volunteers
- 1,000 people
- Sponsor
- French Africa Pediatric Oncology Group
Relapsed/Refractory B- Cell Non-Hodgkin Lymphoma
To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)
A Phase II Open-Label Single-arm Study to Evaluate Safety and Efficacy of locally manufactured autologous CD19-directed CAR T-cells in Patients with Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL) or patients not eligible for…
- Trial name
- CAR-T for NHL (NCT06698484)
- Testing
- CAR-T cells
- Where
- Malaysia
- Volunteers
- 20 people
- Sponsor
- National University of Malaysia
Chronic Lymphocytic Leukemia (CLL)
PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab
Investigational Drugs: Ofatumumab (Azerra) + bendamustine (Trenda) Route of Administration: Intravenous (IV) Hypothesis: This study is designed to assess the toxicity and overall response rate.
- Trial name
- NCT01131247
- Testing
- ofatumumab + bendamustine
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Nevada Cancer Institute
Advanced Solid Tumor, Lymphoma
A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas
DS-3078a will be evaluated as a single agent in subjects with advanced solid tumor malignancies or lymphomas refractory to standard treatment or for which no standard treatment is available.
- Trial name
- NCT01588678
- Testing
- DS-3078a
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Daiichi Sankyo
Lymphoma
Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00007852
- Testing
- rituximab, carmustine, cytarabine
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of Nebraska
Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma
The choice of the best second-line therapy in patients with high LH R/R risk, it is a niche of knowledge not covered at the moment, especially the role of Brentuximab (BV) plus PD-1 blockade and auto-HSCT.
- Conditions
- Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult
- Trial name
- NCT05595447
- Testing
- Brentuximab Vedotin 50 MG [Adcetris]
- Where
- Mexico
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Hospital Regional de Alta Especialidad del Bajio
Advanced Cancer, Gastric Cancer
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer
This Phase I/Ib study is a Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination with Capecitabine, Given Orally on a Daily Schedule in Patients…
- Conditions
- Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer
- Trial name
- GEN602 (NCT03775525)
- Testing
- GZ17-6.02, Capecitabine
- Where
- 4 sites in United States
- Volunteers
- 127 people
- Sponsor
- Genzada Pharmaceuticals USA, Inc.
Non Hodgkin's Lymphoma, Hodgkin Disease
Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant
The proposed study is based on our observation of paradoxical tumor regression after rejection of the donor graft in conjunction with the results of our murine experiments.
- Conditions
- Non Hodgkin's Lymphoma, Hodgkin Disease, Multiple Myeloma
- Trial name
- RLI (NCT00909948)
- Testing
- Fludarabine and total body irradiation, Total body irradiation
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Massachusetts General Hospital
Cutaneous T Cell Lymphoma
Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)
This is a single-center, phase I/IB study to identify the recommended phase II dose of Ropeginterferon-alfa 2b (P1101) in patients with CTCL who have failed at least two prior lines of skin-directed therapy (Stage IA-IB) or have…
- Trial name
- NCT07047885
- Testing
- Ropeginterferon alfa-2b
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Non-hodgkin Lymphoma, Peripheral T-cell Lymphoma
Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma
In this study, the XNW5004 tablets combined with CHOP/CHOEP will be used for the treatment of newly diagnosed PTCL patients.
- Trial name
- NCT07730515
- Testing
- XNW5004 combined with CHOP (incremental), XNW5004 combined with CHOEP (incremental), XNW5004 combined with CHOP (extended)
- Where
- China
- Volunteers
- 176 people
- Sponsor
- Evopoint Biosciences Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.